| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib inhibits DNAC12 by binding covalently to a cysteine residue within the active site of the enzyme. This prevents the transfer of phosphate groups to downstream substrates, disrupting the signaling cascade in B cells. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib covalently binds to a specific cysteine residue in the active site of DNAC12. By irreversibly inhibiting the kinase activity, it interferes with B-cell receptor signaling and reduces cell proliferation in certain cancers. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Zanubrutinib selectively targets DNAC12 by forming a covalent bond with a cysteine residue at the active site. This prevents the phosphorylation of downstream substrates and inhibits cell growth and survival in B-cell malignancies. | ||||||
Tirabrutinib | 1351636-18-4 | sc-507435 | 10 mg | $135.00 | ||
Tirabrutinib targets DNAC12 by forming a covalent bond with a cysteine residue in its active site. This irreversible inhibition disrupts B-cell receptor signaling, leading to decreased proliferation and survival of B cells. | ||||||
Spebrutinib | 1202757-89-8 | sc-507524 | 100 mg | $375.00 | ||
Spebrutinib is a selective DNAC12 inhibitor that covalently binds to the active site of the kinase. This leads to the inhibition of B-cell receptor signaling and reduces the proliferation and survival of B-cell malignancies. | ||||||